A research team at the University of Cologne's Center for Molecular Medicine Cologne (CMMC) has discovered that the protein ...

Lymphocyte growth rate after CAR-T therapy predicts survival and toxicity in lymphoma. Discover how this biomarker could ...

Researchers assessed the safety and efficacy of the novel PolaR-ICE regimen among patients with relapsed or refractory DLBCL in the second-line setting.

New methods of classifying patients could pave the way for more personalized treatment approaches, a new report states. The methods of subtyping diffuse large B-cell lymphoma (DLBCL) have changed over ...

Researchers found that loss of HDAC7 disrupted B-cell maturation in mouse models. Restoring HDAC7 suppressed tumor growth, ...

The authors say their 3D model improves on results using traditional 2-dimensional approaches. A new report suggests a microfluid platform could be a meaningful tool to screen potential new therapies ...

Editor’s note: This is an automatically generated transcript. Please notify editor@healio.com if there are concerns regarding accuracy of the transcription. We are so lucky in DLBCL to make more rapid ...

Refractory and relapsed DLBCL both present several treatment challenges, but available and upcoming options may help improve outcomes. Diffuse large B-cell lymphoma (DLBCL) is a subtype of non-Hodgkin ...

The 3-year event-free survival was 100% when ibrutinib (Imbruvica) was added to standard treatment for two genetic subtypes of diffuse large B-cell lymphoma (DLBCL) among patients age 60 years or ...

Add Yahoo as a preferred source to see more of our stories on Google. The trial evaluated epcoritamab as a monotherapy against R-GemOx Danish biotechnology company Genmab has announced top line ...

Pivotal studies testing new options in previously untreated double-expressor (MYC/BCL2) diffuse large B-cell lymphoma (DLBCL) yielded differing results, according to findings presented at the recent ...